German pharmaceutical technology company LTS Lohmann is expanding its operations in the United States through the acquisition of Renaissance Lakewood, a New Jersey-based contract development and manufacturing organization (CDMO). The acquisition is aimed at strengthening LTS’s production network and enhancing its range of drug delivery technologies.
LTS, whose core business focuses on developing and manufacturing drug delivery systems, announced that it will acquire Renaissance for an undisclosed amount. The deal is expected to close before the end of November. With this addition, LTS will incorporate Renaissance’s Lakewood, New Jersey, site into its existing group of facilities in Germany, Israel, and the U.S., where it currently operates plants in West Caldwell, New Jersey, and St. Paul, Minnesota, according to a company press release.
Renaissance, founded in 1979, is headquartered in Lakewood, New Jersey, where its production campus is also located. The company specializes in manufacturing unit-dose, bi-dose, and multi-dose nasal sprays, as well as small-volume parenteral fill-finish vials. It also offers R&D formulation development and spray characterization through its laboratories.
According to LTS, the acquisition will bring approximately 500 Renaissance employees into its organization. The move is expected to broaden LTS’s drug delivery portfolio and strengthen its position in the CDMO market. Renaissance operates more than 310,000 square feet of manufacturing, laboratory, and support space across its New Jersey site.
In announcing the acquisition, LTS Chief Executive Bas van Buijtenen stated, “This acquisition marks a significant step in our strategy to expand our CDMO capabilities and strengthen our position as a global leader in innovative drug delivery solutions.” He added that Renaissance’s expertise in nasal sprays and sterile dosage forms aligns with LTS’s current capabilities and will help the company provide greater value to partners and patients worldwide.
The announcement comes at a time when U.S. pharmaceutical manufacturing activity has been increasing across the sector. Much of the investment in domestic production has been driven by the possibility of import tariffs on pharmaceuticals under the Trump administration. For larger branded drug manufacturers, those concerns have led to the development of new production sites in the country.
For CDMOs and producers of generic and biosimilar medicines, mergers and acquisitions have been a common approach to expand U.S. manufacturing capacity in 2025.
Recent transactions include the purchase of a North Carolina drug factory by U.K.-based OXB (formerly Oxford Biomedica) from National Resilience, a production plant in Phoenix, Arizona, acquired by Spanish company Laboratorios Farmacéuticos Rovi from Bristol Myers Squibb, and the acquisition of an Eli Lilly drug substance plant in Branchburg, New Jersey, by Korea’s Celltrion. In addition, Ypsomed, a Swiss drug delivery company, announced plans to invest in building its first U.S. manufacturing plant in Holly Springs, North Carolina.
These developments follow a September announcement by President Donald Trump, who stated that companies would face a 100% import tariff on branded pharmaceutical products shipped from abroad unless they are actively establishing manufacturing facilities in the United States.
Looking forward, LTS now faces the challenge of integrating Renaissance’s operations smoothly while preserving its culture and quality standards. The company may invest in upgrading the Lakewood facility’s biotech capabilities, such as adding more sterile injectable lines or adapting to larger volume outputs. Further, LTS could use the U.S. footprint as a strategic hub to serve North American biotech and pharma customers more directly, reducing lead times and logistical complexity.
Beyond just expansion, LTS might leverage synergies between its European and U.S. operations—sharing process innovation, cross-training staff, and optimizing supply chains. Such integration could drive cost efficiencies, improve technology transfer speed, and ultimately strengthen LTS’s competitive edge in drug delivery services. This move also signals to the CDMO market that LTS is serious about scaling and competing globally—not just in Europe but in the heart of pharma production in the U.S.
